| Literature DB >> 34189022 |
Nasrin Sargazi1, Amirhossein Takian1,2,3, Mehdi Yaseri4, Rajabali Daroudi1, Ali Ghanbari Motlagh5,6, Azin Nahvijou7, Kazem Zendehdel7,8,9.
Abstract
This study aimed to identify mothers' preferences and willingness-to-pay (WTP) for human papillomavirus (HPV) vaccines (in this case, bivalent and quadrivalent) in Iran. We used a discrete choice experiment (DCE) method to present mothers with choices between two hypothetical profiles of vaccines, described by combinations of five attributes, each with two or three levels. We analyzed the DCE results using conditional logistic regression and measured WTP estimates for each attribute. Our response rate was 53.96%, while the completion rate for questioner was 93.57%. We identified protection against cervical cancer, protection against genital warts, protection duration, serious side effects, and cost to influence mothers' preferences for HPV vaccination. The relative importance for serious side effects was the highest among all attributes. Mothers' WTP for bivalent and quadrivalent HPV vaccines was in US $ -432 (US $1 = IRR 42,000) and US $ 380, respectively. Quadrivalent vaccination could be the most suitable candidate for implementing the national immunization schedule. The reason is that mothers express more WTP for the quadrivalent vaccine than bivalent due to its protection against genital warts.Entities:
Keywords: Discrete choice experiment; HPV; Iran; Vaccine; Willingness-to-pay
Year: 2021 PMID: 34189022 PMCID: PMC8220373 DOI: 10.1016/j.pmedr.2021.101438
Source DB: PubMed Journal: Prev Med Rep ISSN: 2211-3355
Attributes and levels for the HPV vaccine.
| Attribute | Level |
|---|---|
| Protection against cervical cancer | 50, 70, 90 (%) |
| Protection against genital warts | 0, 90 (%) |
| Protection duration | 6 ,25, 100 (year) |
| Serious side effects | 1:750,000, 1:150.000, 1:30,000 |
| Cost | 0, 95, 167 |
Sample of the choice set used in this study.
| Vaccine B | Vaccine A | Attributes |
|---|---|---|
| 70% | 50% | Protection against cervical cancer |
| 0% | 90% | Protection against genital warts |
| 25 year | 100 year | Protection duration |
| 1:150000 | 1:150000 | Serious side effects |
| US $ 0 | US $ 167 | Cost |
| Which vaccine do you prefer? |
Characteristics of respondents (n = 306).
| Variables | N (%) |
|---|---|
| Age (y) | |
| 20–30 | 37 (12.1) |
| 31–40 | 206 (67.3) |
| 41–50 | 58 (19) |
| 51–60 | 5 (1.6) |
| Marital status | |
| Married | 296 (96.7) |
| Widowed/Divorced/Separated | 10 (3.3) |
| Education | |
| Elementary education ≤ 5 years | 52 (17) |
| Secondary education ≤ 8 years | 62 (20.3) |
| High school diploma ≤ 12 years | 134 (43.8) |
| University education | 58 (18.9) |
| Employment status | |
| Civil servant | 20 (6.5) |
| Private firm | 17 (5.6) |
| Homemaker | 269 (87.9) |
| Monthly household income, US $ | |
| >80 | 69 (22.6) |
| 80–161 | 120 (39.2) |
| 161–321 | 91 (29.7) |
| 321–562 | 17 (5.6) |
| 562> | 9 (2.9) |
| Family size | |
| ≤4 | 208 (68) |
| ≥5 | 98 (32) |
| Head of household | |
| Yes | 15 (4.9) |
| No | 291 (95.1) |
Coefficients from conditional logit vaccine preference model.
| Attribute | Coefficient | P value | Odd Ratio | 95% confidence interval |
|---|---|---|---|---|
| Protection against cervical cancer | ||||
| 70% | 0.3986 | <0.001 | 1.49 | 1.27–1.73 |
| 90% | 0.596 | <0.001 | 1.81 | 1.47–2.23 |
| Protection against genital warts | ||||
| 90% | 0.9179 | <0.001 | 2.50 | 2.24–2.79 |
| Protection duration | ||||
| 25 year | 0.508 | <0.001 | 1.66 | 1.42–1.94 |
| 100 year | 0.8272 | <0.001 | 2.28 | 1.92–2.71 |
| Serious side effects | <0.001 | |||
| 1:150000 | − 0.7079 | <0.001 | 0.49 | 0.42–0.57 |
| 1:30000 | − 1.3946 | <0.001 | 0.24 | 0.20–0.29 |
| Cost | −0.00113 | 0.033 | 0.99 | 0.99–1 |
Fig. 1Relative importance of attributes.
WTP for the attributes of HPV vaccine.
| Attribute | Coefficient | Average WTP, US $ |
|---|---|---|
| Protection against cervical cancer | 0.596 | 527.43 |
| Protection against genital warts | 0.9179 | 812.3 |
| Protection duration | 0.8272 | 732.03 |
| Serious side effects | 1.3946 | −1234.15 |
WTP for bivalent and quadrivalent vaccines.
| Attribute | WTP for bivalent vaccine, US $ | WTP for quadrivalent vaccine, US $ |
|---|---|---|
| Protection against cervical cancer (70%) | 352.74 | 352.74 |
| Protection against genital warts (90%) | 0 | 812.3 |
| Protection duration (25 year) | 449.55 | 449.55 |
| Serious side effects (1:30000) | −1234.15 | −1234.15 |
| Total WTP | −431.85 | 380.44 |